Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 1mg | $206.00 | In Stock | 1 | |
| 5mg | $404.00 | In Stock | 1 | |
| 10mg | $720.00 | In Stock | 1 | |
| 20mg | $1,249.00 | In Stock | 1 |
ABT-072 is a nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus.
ABT-072 inhibits non-nucleoside NS5B polymerase, and yields antiviral effects[1].
[1]. Min Gao, et al. Combinations of Hepatitis C Virus Inhibitors. US 20120196794 A1
Cell experiment: | To determine compound efficacy, HCV replicon cells are plated at a density of 104 per well in 96-well plates in DMEM media containing 10% FBS. Following incubation overnight, compounds serially diluted in DMSO, or DMSO alone, are added to individual wells to a final DMSO concentration of 0.5%. Cell plates are then incubated at 37°C. for 3 days prior to assaying for cytotoxicity and HCV inhibition. Cell viability is measured using an Alamar Blue assay and CC50 values are calculated using the median effect equation. |
References: [1]. Min Gao, et al. Combinations of Hepatitis C Virus Inhibitors. US 20120196794 A1 | |